Press releases

Stockholm - 10 April 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the US patent and trademark office has issued a notice that they intend to grant additional patents to Oncopeptides AB in the US. Oncopeptides has previously received the corresponding patent protection both in Japan and Europe

Stockholm — 27 February 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that data from its Phase II HORIZON study and Phase I/II ANCHOR study evaluating the company’s novel candidate melflufen, a peptide-conjugated alkylator belonging to the novel class of peptidase enhanced

Stockholm – February 25, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Jakob Lindberg, CEO at Oncopeptides, will present the company at Cowen and Company 39th Annual Healthcare Conference in Boston on March 11th at 4:10 pm Eastern Standard Time, the presentation will be webcasted

Summary of Q4 Financial overview October 1 – December 31, 2018 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 111.4 M (loss: 66.2) Loss per share, before and after dilution, was 2.53 (loss: 1.68) SEK On December 31 cash and cash equivalents amounted to SEK 375.6 M (404.1)

Stockholm —18 February 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the Company will release its Year-end Report on 22 February at 8:00 am CET. The report will be available on the Company’s web site at www.oncopeptides.com

Stockholm —31 January, 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 4,750,000 shares, which was carried out in January 2019

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

Stockholm – December 13, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) will hold its Capital Markets Day in New York tomorrow, Dec 14, between 14:30 – 17:00 CET (8:30-11:00 ET). For those who cannot attend in New York, you can follow this via a webcast. The registration for this webcast is made through notification via the company's website or by using the link below

Stockholm, Sweden –December 5, 2018 – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held today, at Tändstickspalatset in Stockholm. At the Extraordinary General Meeting, the following principal resolutions were passed